本帖最后由 老马 于 2013-3-13 13:43 编辑
; l. E. R r/ K8 Y4 E/ A2 w& H: s/ e' t$ a
健择(吉西他滨)+顺铂+阿瓦斯汀" p' D& V# ~/ |5 Q$ {8 p
Gemzar +Cisplatin + Avastin
% f1 Q! {5 S; }http://annonc.oxfordjournals.org/content/21/9/1804.full# j- {7 m3 C7 B) e0 b1 k
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
R4 @# v( o) ]8 ~2 f! fPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ; \' z2 J D6 P
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. # g+ f$ n3 z/ e- b+ X* z
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 833)
5 s+ L+ j1 ~% H0 I. a! x, x华为网盘附件:7 z) p* x/ _+ Y" r
【华为网盘】ava.JPG, ]2 C9 x9 F2 A2 U3 t' C
|